Increased BACE1-AS long noncoding RNA and β-amyloid levels in heart failure

Cardiovascular Research

Volumn 113, Issue 5, 2017, Pages 453-463

  Greco, Simona ^a   Zaccagnini, Germana ^a   Fuschi, Paola ^a   Voellenkle, Christine ^a   Carrara, Matteo ^a   Sadeghi, Iman ^a   Bearzi, Claudia ^b   Maimone, Biagina ^a   Castelvecchio, Serenella ^a   Stellos, Konstantinos ^c   Gaetano, Carlo ^c   Menicanti, Lorenzo ^a   Martelli, Fabio ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b CNR   (Italy)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Amyloid; BACE1; BACE1 AS; Heart failure; Long noncoding RNA

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; BETA SECRETASE 1; COMPLEMENTARY RNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; LONG UNTRANSLATED RNA; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BACE1 PROTEIN, MOUSE; BACE1-AS LONG NON-CODING RNA, HUMAN; LONG NON-CODING RNA BACE1-AS, MOUSE; MESSENGER RNA; SECRETASE; TRANSCRIPTOME;

AGED; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA REPAIR; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENE SILENCING; HEART FAILURE; HEART INFARCTION; HEK293T CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; BLOOD; CASE CONTROL STUDY; CELL CULTURE; CELL SURVIVAL; DISEASE MODEL; GENETIC TRANSFECTION; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; RNA INTERFERENCE; UPREGULATION;

AGED; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; APOPTOSIS; ASPARTIC ACID ENDOPEPTIDASES; CASE-CONTROL STUDIES; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; HEART FAILURE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MICE; MIDDLE AGED; MYOCYTES, CARDIAC; RNA INTERFERENCE; RNA, LONG NONCODING; RNA, MESSENGER; TRANSCRIPTOME; TRANSFECTION; UP-REGULATION;

EID: 85019120603     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvx013     Document Type: Article

References (51)

1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13:368-378
2. Creemers EE, Wilde AA, Pinto YM. Heart failure: advances through genomics. Nat Rev Genet 2011;12:357-362
3. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74
4. Greco S, Gorospe M, Martelli F. Noncoding RNA in age-related cardiovascular diseases. J Mol Cell Cardiol 2015;83:142-155
5. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol 2010;220:126-139
6. Dimmeler S, Marian AJ, Olson E, Thum T, Condorelli G. Long noncoding RNAs and MicroRNAs in cardiovascular pathophysiology. Circ Res 2015;116:751-763
7. Papait R, Kunderfranco P, Stirparo GG. Long noncoding RNA: a new player of heart failure? J Cardiovasc Transl Res 2013;6:876-883
8. Beltrami C, Angelini TG, Emanueli C. Noncoding RNAs in diabetes vascular complications. J Mol Cell Cardiol 2014;89:1-9
9. Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang C-P, Dorn GW 2nd, Thum T, Heymans S. Long noncoding RNAs in cardiac development and ageing. Nat Rev Cardiol 2015;12:415-425
10. Greco S, Zaccagnini G, Perfetti A, Fuschi P, Valaperta R, Voellenkle C, Castelvecchio S, Gaetano C, Finato N, Beltrami AP, Menicanti L, Martelli F. Long noncoding RNA dysregulation in ischemic heart failure. J Transl Med 2016;14:183
11. Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, Finch CE, St G, Iii L, Paul J. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of b-secretase expression. Nat Med 2008;14:723-730
12. Faghihi MA, Zhang M, Huang J, Modarresi F, Van der Brug MP, Nalls MA, Cookson MR, Laurent G, Wahlestedt C. Evidence for natural antisense transcriptmediated inhibition of microRNA function. Genome Biol 2010;11:R56
13. Cole SL, Vassar R. Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1. Neurobiol Aging 2009;30:1535-1544
14. Cole SL, Vassar R. The basic biology of BACE1: a key therapeutic target for Alzheimer's disease. Curr Genom 2007;8:509-530
15. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 1997;3:1016-1020
16. Rusanen M, Kivipelto M, Levalahti E, Laatikainen T, Tuomilehto J, Soininen H, Ngandu T. Heart diseases and long-term risk of dementia and Alzheimer's disease: a population-based CAIDE study. J Alzheimers Dis 2014;42:183-191
17. Cermakova P, Eriksdotter M, Lund LH, Winblad B, Religa P, Religa D. Heart failure and Alzheimer's disease. J Intern Med 2015;277:406-425
18. Stamatelopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, Gatsiou A, Sopova K, Kotakos C, Varounis C, Tellis CC, Kastritis E, Alevizaki M, Tselepis AD, Alexopoulos P, Laske C, Keller T, Kastrati A, Dimmeler S, Zeiher AM, Stellos K. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol 2015;65:904-916
19. Greco S, Fasanaro P, Castelvecchio S, D'Alessandra Y, Arcelli D, Di Donato M, Malavazos A, Capogrossi MC, Menicanti L, Martelli F. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 2012;61:1633-1641
20. Limana F, Germani A, Zacheo A, Kajstura J, Di Carlo A, Borsellino G, Leoni O, Palumbo R, Battistini L, Rastaldo R, Muller S, Pompilio G, Anversa P, Bianchi ME, Capogrossi MC. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit and thorn cell proliferation and differentiation. Circ Res 2005;97:e73-e83
21. Yan R, Vassar R. Targeting the b secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 2014;13:319-329
22. Porta EA. Pigments in aging: an overview. Ann N Y Acad Sci 2002;959:57-65
23. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 2008;117:2743-2751
24. Agnetti G, Halperin VL, Kirk JA, Chakir K, Guo Y, Lund L, Nicolini F, Gherli T, Guarnieri C, Caldarera CM, Tomaselli GF, Kass DA, Van Eyk JE. Desmin modifications associate with amyloid-like oligomers deposition in heart failure. Cardiovasc Res 2014;102:24-34
25. McLendon PM, Robbins J. Proteotoxicity and cardiac dysfunction. Circ Res 2015;116:1863-1882
26. Gregory C. Apoptosis: the molecular basis of cell death. In LD, Tomei FO, Cope (eds). Curr Commun Cell Mol Biol New York: Cold Spring Harbor Laboratory, 1991
27. Liu TE, Huang Y, Chen J, Chi H, Yu Z, Wang J, Chen C. Attenuated ability of BACE1 to cleave the amyloid precursor protein via silencing long noncoding RNA BACE1-AS expression. Mol Med Rep 2014;10:1275-1281
28. Nural-guvener HF, Mutlu N, Gaballa MA. BACE1 levels are elevated in congestive heart failure. Neurosci Lett 2012;532:7-11
29. Troncone L, Luciani M, Coggins M, Wilker EH, Ho C-Y, Codispoti KE, Frosch MP, Kayed R, Monte F. Ab amyloid pathology affects the hearts of patients with Alzheimer's disease. J Am Coll Cardiol 2016;68:2395-2407
30. Nogalska A, Engel WK, Askanas V. Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers-possibly caused by endoplasmic reticulum stress. Neurosci Lett 2010;474:140-143
31. Vattemi G, Engel WK, Mcferrin J, Pastorino L, Buxbaum JD, Askanas V. BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol 2003;179:150-158
32. Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006;66:S39-S48
33. Kokjohn TA, Vickle GD, Maarouf CL, Kalback WM, Hunter JM, Daugs ID, Luehrs DC, Lopez J, Brune D, Sue LI, Beach TG, Castano EM, Roher AE. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta 2011;1812:1508-1514
34. Roher AE, Esh CL, Kokjohn TA, Castano EM, Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo Y-M, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 2009;5:18-29
35. Philippen LE, Dirkx E, Costa-Martins PA, Windt LJ. Non-coding RNA in control of gene regulatory programs in cardiac development and disease. J Mol Cell Cardiol 2015;89:51-58
36. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866
37. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-489
38. Gianni D, Li A, Tesco G, McKay KM, Moore J, Raygor K, Rota M, Gwathmey JK, Dec GW, Aretz T, Leri A, Semigran MJ, Anversa P, Macgillivray TE, Tanzi RE, del Monte F. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation 2010;121:1216-1226
39. Monte F, Agnetti G. Protein post-translational modifications and misfolding: new concepts in heart failure. PROTEOMICS-Clin Appl 2014;8:534-542
40. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A, Robbins J. Desminrelated cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A 2004;101:10132-10136
41. Zhang B, Bian X, He P, Fu X, Higuchi K, Yang X, Li D. The toxicity mechanisms of action of Ab25-35 in isolated rat cardiac myocytes. Molecules 2014;19:12242-12257
42. Hayashi SI, Sato N, Yamamoto A, Ikegame Y, Nakashima S, Ogihara T, Morishita R. Alzheimer disease-associated peptide, amyloid b40, inhibits vascular regeneration with induction of endothelial autophagy. Arterioscler Thromb Vasc Biol 2009;29:1909-1915
43. Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, Fine RE. Toxicity of various amyloid B peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of Dutch-type mutant. J Neurosci Res 2000;60:804-810
44. Soriano FX, Galbete JL, Forloni G. Effect of b-amyloid on endothelial cells: lack of direct toxicity, enhancement of MTT-induced cell death and intracellular accumulation. Neurochem Int 2003;43:251-261
45. Dawkins E, Small DH. Insights into the physiological function of the b-amyloid precursor protein: beyond Alzheimer's disease. J Neurochem 2014;129:756-769
46. Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener 2007;2:22
47. Mizusawa Y, Horie M, Wilde AAM. Genetic and clinical advances in congenital long QT syndrome. Circ J 2014;78:2827-2833
48. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, Han S, Liu L, Chen Z, Rickman CB, Golde T, Grant MB, Saftig P, Serneels L, Strooper B, Joussen AM, Boulton ME. b-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 2012;4:980-991
49. Hu X, He W, Luo X, Tsubota KE, Yan R. BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway. Cell Rep 2013;4:40-49
50. Zhou L, Barao S, Laga M, Bockstael K, Borgers M, Gijsen H, Annaert W, Moechars D, Mercken M, Gevaer K, Strooper B. The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem 2012;287:25927-25940
51. Wang C, Wang X. The interplay between autophagy and the ubiquitin-proteasome system in cardiac proteotoxicity. Biochim Biophys Acta 2015;1852:188-194